SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
ALTA BIOPHARMA PARTNERS III LP

(Last) (First) (Middle)
ONE EMBARCADERO CENTER
SUITE 3700

(Street)
SAN FRANCISCO CA 94111

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Aegerion Pharmaceuticals, Inc. [ AEGR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/15/2012
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/15/2012 S 55,626 (1) D $17.54 (1) 2,408,426 D (2) (3)
Common Stock 10/16/2012 S 128,229 (4) D $18.67 (4) 2,280,197 D (2) (3)
Common Stock 10/15/2012 S 3,736 (1) D $17.54 (1) 161,742 I (3) (5) See footnote (3) (5)
Common Stock 10/16/2012 S 8,611 (4) D $18.67 (4) 153,131 I (3) (5) See footnote (3) (5)
Common Stock 10/15/2012 S 1,371 (1) D $17.54 (1) 59,350 I (3) (6) See footnote (3) (6)
Common Stock 10/16/2012 S 3,160 (4) D $18.67 (4) 56,190 I (3) (6) See footnote (3) (6)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
ALTA BIOPHARMA PARTNERS III LP

(Last) (First) (Middle)
ONE EMBARCADERO CENTER
SUITE 3700

(Street)
SAN FRANCISCO CA 94111

(City) (State) (Zip)
1. Name and Address of Reporting Person*
PENHOET EDWARD

(Last) (First) (Middle)
ONE EMBARCADERO CENTER, SUITE 3700

(Street)
SAN FRANCISCO CA 94111

(City) (State) (Zip)
1. Name and Address of Reporting Person*
CHAMPSI FARAH

(Last) (First) (Middle)
ONE EMBARCADERO CENTER
SUITE 3700

(Street)
SAN FRANCISCO CA 94132

(City) (State) (Zip)
1. Name and Address of Reporting Person*
HURWITZ EDWARD

(Last) (First) (Middle)
ONE EMBARCADERO CENTER, SUITE 3700

(Street)
SAN FRANCISCO CA 94111

(City) (State) (Zip)
1. Name and Address of Reporting Person*
ALTA BIOPHARMA MANAGEMENT III LLC

(Last) (First) (Middle)
ONE EMBARCADERO CENTER
SUITE 3700

(Street)
SAN FRANCISCO CA 94111

(City) (State) (Zip)
1. Name and Address of Reporting Person*
ALTA BIOPHARMA PARTNERS III GMBH & CO BETEILIGUNGS KG

(Last) (First) (Middle)
ONE EMBARCADERO CENTER
SUITE 3700

(Street)
SAN FRANCISCO CA 94111

(City) (State) (Zip)
1. Name and Address of Reporting Person*
ALTA EMBARCADERO BIOPHARMA PARTNERS III LLC

(Last) (First) (Middle)
ONE EMBARCADERO CENTER
SUITE 3700

(Street)
SAN FRANCISCO CA 94111

(City) (State) (Zip)
1. Name and Address of Reporting Person*
Kiley Alison

(Last) (First) (Middle)
ONE EMBARCADERO CENTER
SUITE 3700

(Street)
SAN FRANCISCO CA 94111

(City) (State) (Zip)
Explanation of Responses:
1. On October 15, 2012, Alta BioPharma Partners III, L.P. ("ABPIII"), Alta BioPharma Partners III GmbH & Co. Beteiligungs KG ("ABMPIIIKG"), and Alta Embarcadero BioPharma Partners III, LLC ("AEBPIII") disposed of 55,626, 3,736 and 1,371 shares of the Issuer's Common Stock, respectively, on the public market at an average price of $17.54 per share. The range of sale prices for the transactions reported was $17.20 to $18.08 per share. The reporting persons undertake to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares sold at each separate price.
2. These securities are beneficially owned by ABPIII.
3. Alta BioPharma Management III, LLC ("ABMIII") is the general Partner of ABPIII, the managing limited partner of ABPIIIKG. Farah Champsi, Edward Penhoet, and Edward Hurwitz are directors of ABMIII and managers of AEBPIII, along with ABPIII and ABPIIIKG shall be known as "the Funds," exercise shared voting and investment power with respect to the securities held by the Funds. Alison Kiley is a member of ABM III. Each of the reporting persons disclaim beneficial ownership of such securities, except to the extend of his, her, or its proportionate pecuniary interest herein.
4. On October 16, 2012, ABPIII, ABMPIIIKG, and AEBPIII disposed of 128,229, 8,611 and 3,160 shares of the Issuer's Common Stock, respectively, on the public market at an average price of $18.67 per share. The range of sale prices for the transactions reported was $18.20 to $19.23 per share. The reporting persons undertake to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares sold at each separate price.
5. These securities are beneficially owned by ABPIIIKG.
6. These securities are beneficially owned by AEBPIII.
Remarks:
by Alta BioPharma Management III, LLC, /s/ Farah Champsi, Director 10/17/2012
/s/ Edward Penhoet 10/17/2012
/s/ Farah Champsi 10/17/2012
/s/ Edward Hurwitz 10/17/2012
/s/ Farah Champsi, Director 10/17/2012
by Alta BioPharma Management III, LLC /s/ Farah Champsi, Director 10/17/2012
/s/ Farah Champsi, Manager 10/17/2012
/s/ Alison Kiley 10/17/2012
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.